S100B, Actor and Biomarker of Mild Traumatic Brain Injury

Mild traumatic brain injury (mTBI) accounts for approximately 80% of all TBI cases and is a growing source of morbidity and mortality worldwide. To improve the management of children and adults with mTBI, a series of candidate biomarkers have been investigated in recent years. In this context, the m...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (7), p.6602
Main Authors: Oris, Charlotte, Kahouadji, Samy, Durif, Julie, Bouvier, Damien, Sapin, Vincent
Format: Article
Language:English
Subjects:
actor
Actors
Actresses
Adipocytes
Adult
Athletes
Athletic recruitment
biomarker
Biomarkers
Brain
Brain Concussion - diagnosis
Brain Injuries - diagnosis
Child
Computed tomography
Concussion
CT imaging
Decision making
France
Humans
Injuries
Medical imaging
Morbidity
Mortality
Musculoskeletal system
Pediatrics
Physiology
Proteins
Radiation
Review
S100 Calcium Binding Protein beta Subunit
S100B
S100b protein
Therapeutic targets
Tomography, X-Ray Computed
Trauma
Traumatic brain injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mild traumatic brain injury (mTBI) accounts for approximately 80% of all TBI cases and is a growing source of morbidity and mortality worldwide. To improve the management of children and adults with mTBI, a series of candidate biomarkers have been investigated in recent years. In this context, the measurement of blood biomarkers in the acute phase after a traumatic event helps reduce unnecessary CT scans and hospitalizations. In athletes, improved management of sports-related concussions is also sought to ensure athletes' safety. S100B protein has emerged as the most widely studied and used biomarker for clinical decision making in patients with mTBI. In addition to its use as a diagnostic biomarker, S100B plays an active role in the molecular pathogenic processes accompanying acute brain injury. This review describes S100B protein as a diagnostic tool as well as a potential therapeutic target in patients with mTBI.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24076602